Principles of CRISPR-Cas13 mismatch intolerance enable selective silencing of point-mutated oncogenic RNA with single-base precision
Science Advances · 2024
DOI: 10.1126/sciadv.adl0731 ↗Kurz gefasst
Fachartikel in der Zeitschrift Science Advances, 2024. Verfasst von Carolyn Shembrey und 12 weiteren Autor:innen. Beteiligte Einrichtung: Rosie Lew Program in Immunotherapy and Cancer Cell Death Laboratory, Peter MacCallum Cancer Centre, Melbourne 3000, Australia. Hauptthemen laut MEDLINE: CRISPR-Cas Systems. Die Arbeit wurde bisher 29-mal zitiert (Crossref) und nennt 51 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Single-nucleotide variants (SNVs) are extremely prevalent in human cancers, although most of these remain clinically unactionable. The programmable RNA nuclease CRISPR-Cas13 has been deployed to specifically target oncogenic RNAs. However, silencing oncogenic SNVs with single-base precision remains extremely challenging due to the intrinsic mismatch tolerance of Cas13. Here, we show that introducing synthetic mismatches at precise positions of the spacer sequence enables de novo design of guide RNAs [CRISPR RNAs (crRNAs)] with strong preferential silencing of point-mutated transcripts. We applied these design principles to effectively silence the oncogenic KRAS G12 hotspot, NRAS G12D and BRAF V600E transcripts with minimal off-target silencing of the wild-type transcripts, underscoring the adaptability of this platform to silence various SNVs. Unexpectedly, the SNV-selective crRNAs harboring mismatched nucleotides reduce the promiscuous collateral activity of the Rfx Cas13d ortholog. These findings demonstrate that the CRISPR-Cas13 system can be reprogrammed to target mutant transcripts with single-base precision, showcasing the tremendous potential of this tool in personalized transcriptome editing.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Rosie Lew Program in Immunotherapy and Cancer Cell Death Laboratory, Peter MacCallum Cancer Centre, Melbourne 3000, Australia.
- Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Melbourne 3052 Australia.
- School of Clinical Sciences at Monash Health, Monash University, Clayton, VIC 3168, Australia.
- Children's Cancer Institute, Lowy Cancer Centre, University of New South Wales, Sydney, Kensington, NSW, Australia.
- UNSW Centre for Childhood Cancer Research, University of New South Wales, Sydney, Kensington, NSW, Australia.
ORCID-Profile: Carolyn Shembrey, Ray Yang, Joshua Casan, Teresa Sadras, Krishneel Prasad, Jake Shortt, Ricky W Johnstone, Joseph A Trapani, Paul G Ekert, Mohamed Fareh
Zitieren
APA
Shembrey, C., Yang, R., Casan, J., Hu, W., Chen, H., Singh, G. J., Sadras, T., Prasad, K., Shortt, J., Johnstone, R. W., Trapani, J. A., Ekert, P. G., & Fareh, M. (2024). Principles of CRISPR-Cas13 mismatch intolerance enable selective silencing of point-mutated oncogenic RNA with single-base precision. Science Advances. https://doi.org/10.1126/sciadv.adl0731
Vancouver
Shembrey C, Yang R, Casan J, Hu W, Chen H, Singh GJ, et al. Principles of CRISPR-Cas13 mismatch intolerance enable selective silencing of point-mutated oncogenic RNA with single-base precision. Science Advances. 2024. doi:10.1126/sciadv.adl0731
BibTeX
@article{Shembrey2024,
author = {Shembrey, Carolyn and Yang, Ray and Casan, Joshua and Hu, Wenxin and Chen, Honglin and Singh, Gurjeet J and Sadras, Teresa and Prasad, Krishneel and Shortt, Jake and Johnstone, Ricky W and Trapani, Joseph A and Ekert, Paul G and Fareh, Mohamed},
title = {Principles of CRISPR-Cas13 mismatch intolerance enable selective silencing of point-mutated oncogenic RNA with single-base precision},
journal = {Science Advances},
year = {2024},
doi = {10.1126/sciadv.adl0731}
}
EUVIMED